Purpose: To report the quality of life and visual functioning in uveal melanoma patients treated with enucleation or fractionated stereotactic radiation therapy (fSRT).
Introduction
Quality of life (QoL) is highly subjective and a dynamic process, subject to changes in life and life events. Yearly, 6-7 people per million are diagnosed with uveal melanoma (UM) (Singh & Topham 2003) . The survival is generally not influenced by the treatment strategy chosen for the primary tumour (Furdova et al. 2010 ). In the early days, enucleation was the standard treatment for UM. Nowadays, several eye sparing treatment modalities are available with the main purpose of sparing visual function. The decision to have the eye enucleated is inevitable in patients with very large tumours and can be psychologically traumatic. Enucleation and irradiation treatment have different psychological effects on patients, which reflects quality of life (Brandberg et al. 2000; Melia et al. 2006) . However, studies on the exact effect are inconclusive. Questionnaires have been developed to measure patients' well being and could assist, to customize treatment for each patients' need.
Cancer diagnosis led in general to quality of life impairment compared to healthy subjects and patients with other non-oncological ophthalmological con-ditions (Reimer et al. 2006) . Treatment of UM seemed to reduce quality of life at least in the first 3 years after diagnosis (Brandberg et al. 2000; Chabert et al. 2004 ). However, impaired as well as normal quality of life has been found within a 5-year follow-up (Cruickshanks et al. 1999; Reimer et al. 2003) . Nevertheless, 5 years after diagnosis and treatment for UM, quality of life is higher compared to other cancer types (Wiley et al. 2013) . In addition, patients have reported about fear of local recurrence equally after enucleation and conservative treatment (Damato 2000) . Twenty patients in one study revealed that the worst psychological moment (mild to severe state of depression) after enucleation occurred 3 months after surgery. They reported more difficulties in adaptation and more anxiety than after 1 year. One year after enucleation, they appeared to have a a more balanced quality of life (Amaro et al. 2010) . Enucleated patients reported problems with appearance and judging distances one year after treatment (Brandberg et al. 2000) . In addition, 72-85% of the patients report a reduced quality of life and 60-74% experience reduced emotional functioning irrespective of their treatment with Ruthenium plaque or enucleation (Brandberg et al. 2000) . While comparison of the mean levels of quality of life before and after treatment with LINAC, Ruthenium-106 and Gamma Knife showed only 5% decline (Chabert et al. 2004 ). Patients treated with brachytherapy are significantly better in driving and have better peripheral vision than enucleated patients for up to 2 years following treatment (Melia et al. 2006) .
Non-invasive fractionated stereotactic radiation therapy (fSRT) was introduced in our clinic in 1999, as a locoregional treatment for medium and large-sized UM with promising results for tumour control without serious side-effects (Muller et al. 2012) . As enucleation and fSRT offer comparable survival rates, the assessment of patients' physical, mental and overall patients' quality of life is of great importance in treatment decision (Augsburger et al. 1999; Cohen et al. 2003) . There are only few studies that have compared the quality of life of uveal melanoma patients treated with fSRT or enucleation (Chabert et al. 2004) . Therefore, a prospective study was initiated in our clinic to compare the quality of life in patients who underwent an enucleation versus patients treated with fSRT.
Patients and Methods

Design
From February 1st, 2002, all UM patients who visited the tertiary ocularoncology clinic were offered to participate in this quality of life study. All questionnaires were sent to the patients and filled in at home or in the clinic during their follow-up visit. The baseline (pretreatment) measurement took place at the second visit. After starting either treatment (enucleation or fSRT), the questionnaires have been taken after two, six and 12 months, followed by a questionnaire once a year for 4 years after treatment. The first patient was treated on March 8th, 2002 and the latest patient was treated on December 2nd, 2009. This study was approved by the Medical Ethics Committee of the Erasmus MC and was conducted in accordance with the tenants of Declaration of Helsinki. Written informed consent was obtained.
Patients
For fSRT treatment (5 9 10 Gy) a tumour ought to have a thickness smaller than 12 mm and a diameter smaller than 16 mm. Patients with larger tumours underwent enucleation and some patients preferred enucleation after comprehensive counselling about both treatment modalities given by an ophthalmologist and a radiation oncologist. Because of medical-ethical reasons, randomization was not possible. Patients who were initially treated with fSRT and secondarily enucleated were censored at the moment of enucleation. Local recurrence was defined as persisting increase in the tumour on B-scan ultrasonography (US) or enlargement of the tumour on fundoscopy. Disease-free survival (DFS) was defined as the moment of diagnosis until development of metastases or patients' death. Cases in which the cause of death was unknown or not related to their UM were treated as censored. Survival date was obtained until December 1st 2013. Tumour characteristics, the largest tumour diameter (LTD) and the tumour thickness, were measured, using US. Visual acuity of the affected and contralateral eye was measured in fSRT patients and was converted into log Mar.
Questionnaires
The quality of life (QoL) (Julian 2011) . However, higher cut-off points have been suggested as well.
Impact of event scale (IES)
The Dutch version of the IES was used to measure subjective distress after a specific stressor (in this case being treated for UM) (Horowitz et al. 1979; Brandberg et al. 2004; van der Ploeg et al. 2004) . It is a two-factor 'intrusion-avoidance' model consisting of a 15-item self-report questionnaire on a 4-point scale. It measures both intrusion (7 items), characterized by unbidden thoughts and images of the event, troubled dreams, strong pangs or waves of feelings and repetitive behaviour, and avoidance (8 items), characterized by denial of meaning and consequences of the event. The weighted sum of the responses is the scale score, ranging from 0 to 75. Cutoff point of low (0-8), medium (9-19) and high (≥20) levels of distress has been suggested (Joseph 2000) . The EORTC QLQ-C30 is designed for cancer patients and measures the quality of life on multi-item scales, including five functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), a global health/QoL-scale and symptom scales/items about additional symptoms commonly reported by cancer patients (fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties) . All scores range from 0 to 100. The higher scores representing a better quality of life. This is in contrast to the symptom scales. In the symptom scales, higher scores indicate more severe symptoms. Our patients received a Dutch translation of the EORTC QLQ-C30 (Sprangers et al. 1993 ). An example of the role functioning question was for the lowest possible score (0): 'In the past week I was completely unable to work at a job or do household jobs' and was for the highest possible score (100): 'In the past week I was not limited at all doing either work or household jobs'.
National eye institute visual function questionnaire (NEI VFQ-25)
The NEI VFQ-25 is used to measure the influence of the different treatment modalities for UM on patients' functioning and wellbeing (Mangione et al. 1998 (Mangione et al. , 2001 . It consists of 12 subscales from 39 items with 1-6 items per subscale: 2 items in general health, general vision and ocular pain, 6 items in near activities and distance activities, 3 items in social functioning and driving, 5 items in mental health, 4 items in role difficulties and dependency and 1 item in colour vision and peripheral vision. Each item is converted into a 0-100 scale and a higher score represents better functioning.
Statistical methods
Multilevel hierarchical linear regression analyses were applied for longitudinal analyses of the data. This method can efficiently handle missing data and data with unbalanced time-points. There were two levels in the models. The patients constitute the upper level; their repeated measures the lower level. First, a model was postulated for each outcome variable with linear and logarithm of time, treatment (enucleation or fSRT), the occurrence of metastasis and interactions with time as fixed effects. The deviance statistic using restricted maximum likelihood was applied to determine the covariance structure (Verbeke & Molenberghs 2000; Singer & Willett 2003) . Effect sizes were calculated from dividing differences between time-point estimations and baseline by the estimated baseline standard deviation. For the interpretation of the effects sizes the definition of Cohen was used: an effect size of 0.20 is considered a small effect, 0.50 medium and 0.80 a large effect (Cohen 1992) . A Cox regression analysis was performed to analyse the difference in DFS between fSRT and enucleation. To correct for the confounding effect of the largest tumour diameter, tumour thickness and treatment on DFS, all factors were entered as a covariate. Statistical analyses were performed with IBM-SPSS release 21 (SPSS Inc, Chicago, Ill).
Results
Patient and tumour characteristics
In total, 116 patients participated in this prospective study. Three patients withdrew after receiving the first questionnaire. The study included 113 patients (60 men and 53 women). Baseline characteristics are shown in Table 1 . There was no difference in gender between the two groups (p = 0.056, Table 1 ). The overall mean age was 65 years at time of treatment (range 33-89 years). Patients were treated with either fSRT (58%) or enucleation (42%). Thirteen patients treated with fSRT underwent a secondary enucleation due to tumour progression (n = 4) or complications (painful neovascular glaucoma (n = 8), endophthalmitis after cataract surgery (n = 1)) after a median period of 29.2 months (range 9.3-63.4 months). Three patients were lost to follow up. One patient stopped after questionnaire 2 due to migration and one patient stopped after questionnaire 5 for unknown reason. The last patient finished the questionnaires, however was lost to follow up 8 years posttreatment. Questionnaires were included until the last date of follow-up. Figure 1 illustrates the number of completed questionnaires until 4 years posttreatment. A significant larger mean LTD was observed in tumours treated with enucleation compared to fSRT-treated tumours, respectively 13.4 mm versus 11.9 mm (p = 0.017, independent sample t-test). The mean tumour thickness was equal in both groups (p = 0.061, independent sample t-test). Patients treated with enucleation metastasized significantly more often than patients treated with fSRT (56% versus 26%, p = 0.006, Chi-square test). The disease-free survival in enucleated patients ranged from 5.2-124.6 months and in fSRT patients from 3.2-133.1 months. Univariate analysis showed a significantly shorter mean survival (69.5 months) in patients who underwent an enucleation (95% CI, 56.7-83.2, X 2 : 12.49, p < 0.001, log rank test). However, when corrected for largest tumour diameter and tumour thickness there was no significant difference in survival between both treatment options (Hazard ratio (HR) = 1.78, p = 0.099, Cox proportional hazard model). In multivariate analysis, only largest tumour diameter was related with survival (HR = 1.32, <0.001, Cox proportional hazard model).
Anxiety level
STAI
A reduction in state anxiety (the current state of anxiety) was measured from pretreatment until 2 years after treatment in both treatment groups (pretreatment: 44.4, 95% CI, 42.3-46.4 and at 2 years 37.5, 95% CI, 35.5-39.5, p < 0.001). Between pretreatment and until 4 years after treatment a medium effect (Cohen's D: 0.52) was noted. At baseline, fSRT patients scored (37.3) slightly higher in trait anxiety (anxiety level as a personal characteristic) than enucleated patients (35.7). After 2 years, enucleated patients experienced more trait anxiety than patients treated with fSRT, although this effect was not significant (p = 0.088). There was no significant difference observed between the two treatment groups for trait and state anxiety. When we compared the scores of patients with and without metastases, despite their treatment, patients with metastases were significantly more anxious (state anxiety only) after 3 years (p = 0.026, Students' t-test) than patients without metastases (Table 2) .
Subjective distress
IES
The 'Intrusion' score as well as the 'Avoidance' score showed no difference for the enucleated and fSRT patients. However, a significant reduction (p < 0.001) for 'Intrusion' and 'Avoidance' scores overall, was noted from pretreatment until 4 years after treatment in all patients. After patients were diagnosed, a medium level of distress was measured, which reduced to a low level 6 months after treatment. At baseline, patients with metastases scored only significantly higher in 'Intrusion' (16.5, 95% CI, 11.5-21.5, versus 5.28, 95% CI, 0.3-10.3, p = 0.037, Students' t-test) than patients without metastases. After this point, we found no significant difference between these two groups.
EORTC QLQ-C30
The scores on the EORTC questionnaire are given in Table 3 . Functional scale. The physical functioning subscale showed no difference between the enucleation and fSRT patients before treatment and during follow-up. However, a decrease in physical functioning was significant (p = 0.035) over time in both treatment groups. At baseline, no significant difference is measured in the subscale role functioning (p = 0.183) between the enucleated and fSRT patients. Figure 2 shows that after 2 months irradiated patients improve significantly in role functioning-score (p = 0.005). On the contrary, enucleated patients showed a significant decrease in role functioning (p = 0.012). However, after 4 years no significant difference between fSRT and enucleated patients was measured (p = 0.063) in scores. In both treatment groups, emotional functioning subscale improves (p < 0.001) from 1 year posttreatment. This effect is the largest after 2 years; Cohen's D is 0.67 after two and 0.53 after 4 years, respectively (medium effect). After 3 years, patients with metastases, regardless of their treatment, scored significantly lower (score 69.9, 95% CI, 64.9-74.9) in emotional functioning compared to patients without metastases (score 83.4; 95% CI, 78.4-88.4, p = 0.022, Student's t-test) ( Table 2 ). In the subscales cognitive and social functioning, we found no significant differences between the treatment options and between patients with and without metastases. Symptom scales and single items. Nausea/vomiting and pain subscales revealed no significant differences between both treatment groups. However, patients with metastases had a significant higher score (10.8, 95% CI, 8.9-13.5, versus 2.5, 95% CI, À0.2 to 5.2) in nausea after 4 years regardless of their treatment modality (p = 0.037, Student's t-test) ( 
years).
The insomnia and appetite loss subscales showed no difference between the enucleation and fSRT patients. A significant decrease in insomnia was measured over time (p < 0.001) for both treatment groups. In contrast, for patients with metastases (independent of which treatment) insomnia increased significantly (p = 0.009, Student's t-test) after two years ( Table 2) . The score for appetite loss increased (p = 0.014, Student's t-test) after 3 years in this group as well (Table 2) . Patients with metastases developed more insomnia and experienced more appetite loss with time than patients without metastases. The subscales: fatigue, dyspnoea, constipation, diarrhoea and financial difficulties revealed no differences between both treatment groups. However, patients with metastases developed less financial difficulties and more diarrhoea after 3 years (p = 0.014).
In the Global health subscale, we found no difference in quality of life between the two treatment groups. The overall global health score, with no effect of time, was 76.4 (SD 13.6) on a scale of 0-100. No significant difference was observed between the patient groups with and without metastases, however the score after 4 years was lower for patients with metastases (71) versus without metastases (78).
Visual functioning
Visual Function Questionnaire
At baseline enucleated patients scored better on the General health subscale, while 2 years after treatment irradiated patients scored better. The difference between these groups was not significant (p = 0.09). The score of fSRT patients declines significantly compared to baseline until 2 years after treatment (p = 0.007), and the score of enucleated patients showed a significant (p < 0.001) decline after 4 years compared to baseline. In addition, patients with or without metastases showed no significant difference.
A significant difference was noted in the peripheral vision domain from baseline (fSRT: 82.6 versus enucleation: 66.9) until 3 years of follow up after treatment between the enucleated (58.9) and fSRT (69.3) patients, (p < 0.001) until 2 years after treatment, and 3 year after treatment (p = 0.026, Student's t-test) (Table 2, Figure 3 ). There was no significant difference between metastasized and non-metastasized patients. All the other domains showed no significant difference between enucleated and fSRT patients with UM and between patients with and without metastases (despite their treatment).
Discussion
In the subscales of the different questionnaires about the quality of life of UM patients treated either with fSRT or enucleation we noted dissimilarities.
The most significant differences were that patients treated with fSRT improved in role functioning from 2 months until 4 years after treatment (p = 0.005; Fig. 2 ) and fSRT patients reported better peripheral vision (p = 0.026; Fig. 3 ) until 3 years after treatment compared to those that were enucleated. Role functioning is significantly (p = 0.012) decreased in patients treated with enucleation. This is comparable with Klingenstein et al., who reported role physical as significant lower in the enucleation group versus stereotactic radiosurgery or control group (Klingenstein et al. 2016) . And this is in contrary with another study where role functioning increased significantly in patients treated with Ruthenium plaque or enucleation during the first year after therapy (Brandberg et al. 2000) .
In contrast to a previous report (Brandberg et al. 2000) regarding peripheral vision, we found that fSRT patients reported a better peripheral vision compared to enucleated patients (Figure 3) . This is not surprising as the eye is conserved with the treatment. These results are in line with The Collaborative Ocular Melanoma Study (COMS), where patients treated with brachytherapy reported better peripheral vision for up to 2 years following treatment than enucleated patients (Collaborative Ocular Melanoma Study 2006). Patients who underwent enucleation adapted to the new situation and got used to using their only remaining eye. Fifteen years after enucleation, 90% retained the ability to drive and 96% retained the ability to read (Edwards & Schachat 1991) .
Cancer patients have reported disturbing sleeping patterns. Poor quality Table 3 . The raw data of the EORTC questionnaire. of sleep was correlated with poor quality of life (Mystakidou et al. 2007 ). In our study, patients with metastases reported a higher score in insomnia compared to the patients without metastases. However, this difference is only significant (p = 0.009, Student's t-test) 2 years after treatment. Other significant differences between those with and without metastatic disease were found for state anxiety, emotional functioning and appetite loss, 3 years after treatment. In addition, patients with metastases experienced more nausea 4 years after their treatment. Cancer-related anxiety may manifest as digestive symptoms, such as nausea (Baqutayan 2012 ). Overall we measured no significant differences in time effect in global health and in quality of life between both treatment groups. However, after four years we found a lower Global health score for patients with metastases (71) versus without metastases (78). Compared to other cancer patients, UM patients reported a substantial better quality of life score. The normative data for the EORTC QLQ-C30 in the general Dutch population shows an overall mean score of Global quality of life of 78 (SD: 17) for men (n = 935) and 77 (SD: 18) for women (n = 796) (van de Poll-Franse et al. 2011) . In this population the lowest global quality of life score was reported in patients with a self-reported depression in the past 12 months (mean: 60, SD: 20). The highest score was noted from people with no reported health problems (mean: 84, SD: 14). In our study, patients with UM reported a mean score of 76.4, which is almost comparable with the Dutch normative data and is higher than the scores of healthy people in Germany or the general population in Norway (Hjermstad et al. 1998; van de Poll-Franse et al. 2011; Waldmann et al. 2013 ). Chabert et al. reported a decline of 5% in quality of life after treatment with either brachytherapy or radiotherapy (Chabert et al. 2004 ). Unfortunately, the EORTC ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30), an extra questionnaire module more specific for quality of life in uveal melanoma patients, was published 5 years after we started our study, and was not available at that moment (Brandberg et al. 2004 ).
The DFS survival was significantly longer in patients treated with fSRT compared to enucleated patients (p < 0.001). However, when we adjusted for largest tumour diameter and tumour thickness, this finding was no longer significant. Enucleated patients had larger tumours and developed metastases more frequently than irradiated patients (Table 1) . A larger tumour is related to a worse survival (Cohen et al. 2003 ). When we analysed the subgroup of patients with metastatic disease, after 1 year an increasing effect is reported with a Cohen's D factor of 0.85 after 4 years of treatment.
Despite the fact that this is not a randomized study, our results indicate that fSRT contributes to a better role functioning from 2 months posttreatment and improved peripheral vision from baseline until 36 months. However, in the Global health subscale, we found no difference in quality of life between the two treatment groups. The overall global health score, with no effect of time, was 76.4 (SD 13.6) on a scale of 0-100. If several treatment options are available for a patient, these results can aid in treatment planning. Until 24 months: p < 0.001 and p = 0.026 at 3 years Fig. 3 . Peripheral vision score of the VFQ-25 questionnaire. A significant difference is noted in peripheral vision from baseline until 3 years after treatment between the enucleated (red dots) and fSRT (blue dots) patients in the first 2 years. Thereafter, there was no significant difference between the two treatment options.
